Table 2.
iGlarLixi: TEAEs leading to treatment discontinuation in the phase 3 controlled studies [27]
| Phase 3 study data | LixiLan-O | ||
|---|---|---|---|
| iGlarLixi (n = 834) | Insulin glargine (n = 832) | Lixisenatide (n = 233) | |
| Gastrointestinal TEAEs, n (%) | 8 (1.0) | 1 (0.1) | 12 (5.2) |
| Nausea, n (%) | 6 (0.7) | 0 | 6 (2.6) |
| Vomiting, n (%) | 2 (0.2) | 0 | 4 (1.7) |
| Diarrhea, n (%) | 1 (0.1) | 0 | 2 (0.9) |
| Skin and subcutaneous disorders, n (%) | 4 (0.5) | 1 (0.1) | 1 (0.4) |
| Urticaria, n (%) | 3 (0.4) | 0 | 1 (0.4) |
Preferred terms with two or more patients in any treatment group
n (%) number and percentage of patients with at least one TEAE, TEAE treatment-emergent adverse event